Condition: Multiple Myeloma · Multiple Myeloma and Malignant Plasma Cell Neoplasms · Multiple Myeloma and Plasma Cell Neoplasm · Sponsor: Peking University First Hospital
This is a prospective, multicenter diagnostic imaging study designed to evaluate the diagnostic accuracy and clinical utility of BCMA-targeted positron emission tomography/computed tomography (PET/CT) in patients with multiple myeloma and related plasma cell disorders. The study aims to non-invasively visualize and quantify whole-body BCMA expression and to assess its role in the detection of active disease and disease heterogeneity.
This description comes directly from the study's public registry record.
Lei Kang, M.D, Ph.D · 86+13811486428 · kanglei@bjmu.edu.cn
Always discuss trial participation with your own doctor first.
| Beijing An Zhen Hospital of the Capital University of Medical Sciences | Beijing, Beijing Municipality, China | Recruiting |
| Beijing Tsinghua Changgung Hospital | Beijing, Beijing Municipality, China | Recruiting |
| Peking University First Hospital | Beijing, Beijing Municipality, China | Recruiting |
| the Second Hospital of Hebei Medical University | Shijiazhuang, Hebei, China | Recruiting |
| First Hospital of Jilin University | Jilin City, Jilin, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07319897